| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 |
| 19 Oct 2026 |
8-K: Regulation FD Disclosure
NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic... |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC |
| 12 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share,... |
| 11 May 2026 |
8-K: Other Events
We have acted as counsel to ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), with respect to certain matters in connection with the Automatic Shelf Registration Statement on Form S-3ASR (File No. 333-284661) (the “Regist... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 |
| 17 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026 |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC |
| 09 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 |
| 21 Jul 2025 |
8-K: Other Events
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 |
| 02 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 23 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, ArriVent BioPharma, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 34,045,193 shares of common stock, par value $0.0001 per share,... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations |
| 28 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEWTOWN SQUARE, PA, April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,... |
Loading...